KB-1139

BCMA-VHH2-hFCm29

45233

Home » Antibodies » BCMA-VHH2-hFCm29

Background of BCMA-VHH2-hFCm29

B-cell maturation antigen (BCMA), also known as TNFRSF17 or CD269, is a member of the tumor necrosis factor receptor (TNFR) superfamily. The ligands for BCMA include B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), with APRIL exhibiting a higher affinity for BCMA. BCMA is predominantly expressed by mature B lymphocytes, showing minimal expression in hematopoietic stem cells and non-hematopoietic tissues. It plays a crucial role in the survival of long-lived bone marrow plasma cells (PCs) but does not significantly influence overall B-cell homeostasis. Membrane-bound BCMA can undergo γ-secretase-mediated shedding from the cell surface, resulting in the circulation of soluble BCMA (sBCMA). This process leads to decreased activation of surface BCMA by APRIL and BAFF. The expression of BCMA is notably elevated in malignant plasma cells compared to normal plasma cells, making it a potential therapeutic target for multiple myeloma (MM) and other plasma cell disorders.

Specifications

Catalog Number	KB-1139
Antibody Name	BCMA-VHH2-hFCm29
Isotype	Human IgG1-FC
FC Muations	Wild Type
Target	BCMA
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Madry C, Laabi Y, Callebaut I, Roussel J, Hatzoglou A, Le Coniat M, et al. The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int Immunol. 1998;10:1693–702.
Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158:727–38.